Current Vaccine Shortages & Delays
This web page contains the latest national information about vaccine supplies and provides guidance to healthcare providers who are facing vaccine shortages or delays.
*Note: Only those vaccines included on the recommended childhood and adolescent immunization schedule are included in this update.
Vaccines are listed in order used for the Childhood and Adolescent Immunization Schedule.
National Vaccine Supply Shortages
|Vaccine||Shortage||Temporary Change From Routine Recommendation|
|Diphtheria, Tetanus, & Pertussis (DTaP and Tdap)||No|
|Haemophilus influenzae type B (Hib)||No|
|Hepatitis B||See note 1|
|Human Papillomavirus (HPV)||No|
|Inactivated Polio (IPV)||No|
|Influenza||No||See current information about influenza|
|Measles, Mumps, & Rubella (MMR)||See note 2||See Q&As about monovalent M-M-R vaccines Oct 2009|
|Meningococcal Conjugated (MCV4)||See note 3|
|Pneumococcal Conjugated (PCV)||No|
|Pneumococcal Polysaccharide (PPV)||No|
|Serogroup B Meningococcal (MenB)||No|
|Td||See note 4||See Guidance for Td Vaccination during 2017 Shortage Aug 2017|
Note1: Merck is not currently distributing its adult Hepatitis B vaccine and does not expect to be distributing adult Hepatitis B vaccine between now and the end of 2018. Additionally, Merck anticipates that its pediatric Hepatitis B vaccine will be unavailable between early August 2017 and early 2018. Merck’s supply of the dialysis formulation of Hepatitis B vaccine, however, is not affected and is expected to remain available. GSK has sufficient supplies of adult and pediatric Hepatitis B vaccines to address these anticipated gap in Merck’s supply of adult and pediatric Hepatitis B vaccines during these time periods; however, preferences for a specific presentation (i.e., vial versus syringe) may not be met consistently during this time. Updated Jul 2017
Note2: Based on input from the ACIP, professional societies, scientific leaders, and customers on October 26, 2009 Merck announced the company has decided not to resume production of ATTENUVAX® (Measles Virus Vaccine Live), MUMPSVAX® (Mumps Virus Vaccine Live), and MERUVAX®II (Rubella Virus Vaccine Live). This science-based decision will support vaccination of the largest group of appropriate individuals. Updated Jan 2010
Note3: GSK has reported that there is a potential for shipping delays of its meningococcal conjugate vaccine, Menveo ®, during late August and September. Sanofi has sufficient supplies of its meningococcal conjugate vaccine, Menactra ®, to address potential supply gaps during this period.
Note4: Tenivac ® vaccine (Tetanus and Diphtheria Toxoids Adsorbed) has been unavailable since November 2016. Grifols, exclusive distributor for the other US-licensed Td vaccine (manufactured by MassBiologics), has been supplying the US market since that time. Based on higher than anticipated demand for Td vaccine over the past several months, Grifols reports that their supply of Td is constrained, and customers are likely to experience shipping delays and partial shipments during August and the first half of September. Sanofi anticipates resuming distribution of their Td vaccine in mid August.
In the United States shortages of many vaccines in the recommended childhood immunization schedule occurred in the past. Some of these shortages were widespread while others were localized. Reasons for these shortages were multi-factorial and included companies leaving the vaccine market, manufacturing or production problems, and insufficient stockpiles. Consequently, some shortages were only specific to one manufacturer.
Shortages of several of these vaccines necessitated temporary changes in recommendations for their use. During that period, summary information about the shortages including projected duration and recommendations for temporary changes in the childhood immunization schedule were provided.
- Questions including those dealing with changes in child care and school requirements necessitated by vaccine supply problems when they occur can be answered by State Health Department immunization programs.
- General immunization questions can be answered by
The CDC Contact Center at 1-800-CDC-INFO
(1-800-232-4636) English and Español
This vaccines shortages page is updated as needed. If you wish to be notified when it is updated, please use enter your email on this page in the box labeled “Get Email Updates”.
The FDA’s web page on Biological Product Shortages provides additional information regarding regulatory issues related to vaccine supply.
Those acronyms and abbrevations not already spelled out above include
- AAFP – American Academy of Family Physicians
- AAP – American Academy of Pediatrics
- ACIP – Advisory Committee on Immunization Practices
- CDC – Centers for Disease Control and Prevention
- FDA – Food and Drug Administration
- GAO – United States General Accounting Office
- GSK – GlaxoSmithKline
- MMRV – Measles, Mumps, Rubella, and Varicella combination vaccine
- MMWR – Morbidity and Mortality Weekly Report
- NCIRD – National Center for Immunization and Respiratory Diseases
- TTY – teletypewriter
- Other acronyms
- Shortages of travel-related vaccines
- Status of Recently Submitted, Licensed, and Recommended Vaccines & Biologics
Red Book® Online
- Influenza Vaccination Recommendations
- Childhood & Adolescent Immunization Schedules
- Adult Immunization Schedule
- Standards for Immunization Practices for children & adolescents and adults [7 pages]
- Page last reviewed: May 16, 2013
- Page last updated: August 15, 2017
- Content source: